

Contents

CHAPTER 1

The Industrial Production of Glucagon

I. MOLLERUP, T. KORNFELT, P. ORESKOV, and H.V. TØTTRUP

With 7 Figures	1
A. Introduction	1
B. Production	1
I. Expression and Fermentation	1
II. Recovery and Purification	1
1. Recovery	1
2. Purification	2
3. Aggregation	3
III. Pharmaceutical Preparations	3
C. Analysis of Recombinant Human Glucagon	3
I. Introduction	3
II. Identification	3
III. Purity	4
1. Microbiological Impurities	4
2. Water	5
3. Chemical Impurities	6
IV. Assay	9
D. Stability	9
References	10

CHAPTER 2

The Glucagon Gene and Its Expression

J. PHILIPPE. With 8 Figures	11
A. Introduction	11
B. Structure	12
I. The Glucagon Gene	12
II. Genes Encoding Peptide Hormones of the Glucagon Superfamily	14
C. Expression	17

I. Tissue-Specific Expression	17
II. A-Cell-Specific Expression	19
III. Regulation of Glucagon Gene Expression	23
1. Regulation by Insulin	23
2. Regulation by the Second Messenger cAMP	24
D. Conclusions	26
References	27

CHAPTER 3

Preproglucagon and Its Processing

D. BATAILLE. With 8 Figures	31
A. Introduction	31
B. Tissue-Specific Post-translational Processing of Proglucagon	32
I. Glucagon-Containing Peptides	32
II. Glucagon-Related Peptides	38
C. Role of Prohormone Convertases in Proglucagon Processing	39
D. Secondary, Postsecretory Processing of Proglucagon-Derived Peptides	41
I. Glucagon (19-29) or Miniglucagon	42
II. Oxyntomodulin (19-37)	44
E. Conclusions	44
References	46

CHAPTER 4

The Glucagon Receptor Gene: Organization and Tissue Distribution

V. IWANIJ. With 4 Figures	53
A. Introduction	53
B. Cloning of the Glucagon Receptor	53
C. Organization of the Glucagon Receptor Gene	60
D. Tissue Distribution of the Glucagon Receptors	61
I. Adipose Tissue Glucagon Receptors	61
II. Kidney Glucagon Receptors	62
III. Pancreatic Islets Glucagon Receptors	62
IV. Brain Glucagon Receptors	63
V. Heart Glucagon Receptors	63
VI. Intestinal Tract Glucagon Receptors	63
E. Tissue Distribution of Glucagon Receptor Transcripts	63
F. Regulation of Glucagon Receptor Gene Expression	65
G. Structure/Function Analysis of the Glucagon Receptor	67
H. Human Glucagon Receptor	69
I. Conclusions	70
References	70

CHAPTER 5

Mode of Action of Glucagon Revisited

F. PECKER and C. PAVOINE. With 14 Figures	75
A. Introduction	75
B. Glucagon Actions Mediated Through Glucagon Receptors	76
I. Glucagon Receptor	76
II. Glucagon Action in Liver	77
1. Glucagon Mobilizes Ca^{2+} in Hepatocytes	77
2. Glucagon Potentiates the Effect of Ca^{2+} -Mobilizing Agonists	78
3. Regulation of the Cyclic-GMP-Inhibited Phosphodiesterase (CGI-PDE) by cAMP-Dependent Phosphorylation in Liver	79
III. Glucagon Action in Heart	79
1. Adenylyl Cyclase Activation Versus cAMP-Phosphodiesterase Inhibition in Heart Cells	79
C. Glucagon is Processed by Its Target Cells	83
D. Action of Mini-glucagon [Glucagon (19-29)] in Liver	85
I. Pharmacological Concentrations of Glucagon Inhibit the Liver Plasma Membrane Ca^{2+} Pump	85
II. Mini-glucagon is the True Effector of the Liver Plasma Membrane Ca^{2+} Pump	86
III. α s- and β γ -Subunits of G Protein Mediate Inhibition of the Liver Ca^{2+} Pump by Mini-glucagon	87
E. Mini-glucagon Action in Heart	89
I. Mini-glucagon is a Component of the Positive Inotropic Effect of Glucagon	89
II. The Sarcolemmal Ca^{2+} Pump, in Heart, Is a Target for Mini-glucagon Action	91
III. Mini-glucagon Produces Accumulation of Ca^{2+} into the Sarcoplasmic Reticulum Stores	93
F. Glucagon and Mini-glucagon Act in Concert	94
G. Conclusion and Perspectives	96
References	98

CHAPTER 6

Pulsatility of Glucagon

P. LEFÈBVRE, G. PAOLISSO, and A.J. SCHEEN. With 3 Figures	105
A. Introduction	105
B. Oscillations in Glucagon Plasma Levels	105
I. Animal Studies	105
II. Human Studies	106
C. Pulsatile Glucagon Secretion In Vitro	106

D. Pulsatile Glucagon Delivery In Vitro	107
E. Pulsatile Glucagon Delivery In Vivo	107
I. Pulsatile Glucagon Administration in Normal Man	107
II. Combined Pulsatile Administration of Glucagon and Insulin in Normal Man	108
III. Pulsatile Administration of Glucagon in Diabetic Patients	109
IV. Pulsatile Administration of Glucagon in Dogs	109
F. Conclusions	112
References	112

CHAPTER 7

Glucagon and Diabetes

P.J. LEFÈBVRE	115
A. Introduction	115
B. Diabetogenic Effects of Glucagon	115
C. The A Cell in Diabetes	117
D. Circulating Glucagon Levels in Diabetes	117
E. Glucagon Dysfunction in Diabetes	118
I. Hyperglucagonemia of Diabetes	118
II. Defective Glucose Counterregulation	120
F. Role of Glucagon Excess in the Metabolic Abnormalities of Diabetes	121
I. Postpancreatectomy Diabetes	121
II. Insulin-Dependent Diabetes	121
III. Non-Insulin-Dependent Diabetes	122
G. Therapeutic Implications	123
I. Insulin-Dependent Diabetes	123
II. Non-Insulin-Dependent Diabetes	123
H. Conclusions	125
References	125

CHAPTER 8

The Search for Glucagon Antagonists

J.M. AMATRUDA and J.N. LIVINGSTON	133
A. Glucagon as a Drug Target	133
B. Search for a Glucagon Antagonist	135
I. Other Effects of Glucagon	135
II. Glucagon-Receptor Knockout Mice	136

Contents	XV
III. Targets for a Glucagon Antagonist	137
1. Synthesis, Processing and Secretion of Glucagon	137
2. Inhibition of the Actions of the Glucagon Receptor	139
IV. Humanized Mice	143
References	144

CHAPTER 9

Glucagon and Glucose Counterregulation

P.E. CRYER. With 2 Figures	149
A. Introduction	149
B. Glycemic Action of Glucagon	150
C. Glucagon Secretion	151
I. Regulatory Mechanisms	151
II. Glycemic Thresholds	153
D. Role of Glucagon in Glucose Counterregulation	153
I. Physiology	153
1. Insulin	153
2. Glucagon	154
3. Epinephrine	154
4. Other Counterregulatory Factors	154
II. Pathophysiology	155
E. Conclusions	155
References	156

CHAPTER 10

Modes of Glucagon Administration

G. SLAMA, D. BENNIS, and P. ZIRINIS. With 2 Figures	159
A. Introduction	159
B. Classic Routes of Administration	160
I. Intravenous Route	160
II. Intramuscular Route	160
III. Subcutaneous Route	161
C. New Routes of Glucagon Administration	162
I. Intranasal Route	162
II. Eye Drops	166
III. Rectal Route	167
D. Conclusions	168
References	169

CHAPTER 11

The Place of Glucagon in Emergency Medicine

M.M. JOHNSON and G.P. ZALOGA	171
A. Hypoglycemia	171
B. Cardiovascular Insufficiency	174
C. Vascular Effects	178
D. Renal/Urologic Effects	180
E. Shock	180
F. Respiratory Effects	181
G. Gastrointestinal Effects	182
H. Radiographic Studies	184
I. Adverse Effects	184
References	184

CHAPTER 12

The Place of Glucagon in Medical Imaging

J. SKUCAS	195
A. Introduction	195
B. Upper Gastrointestinal Tract	195
I. Esophagus	195
II. Stomach and Duodenum	196
C. Small Bowel	198
I. Enteroclysis	198
II. Retrograde Ileography	198
III. Peroral Pneumocolon	199
D. Large Bowel	199
I. Barium Enema	199
II. Intussusception Reduction	200
E. Biliary Tract	201
F. Other Applications	201
I. Computed Tomography	201
II. Ultrasonography	201
III. Angiography	202
IV. Magnetic Resonance Imaging	202
V. Hysterosalpingography	202
VI. Scintigraphy	203
VII. Urography	204
G. Side Effects and Contraindications	204
References	205

CHAPTER 13

The Glucagon Test for Evaluation of Insulin Secretion

A. J. SCHEEN	211
A. Introduction	211
B. Methodological Aspects	211
I. Classical Test	211
II. Dose-Response Curve	212
III. Reproducibility	212
IV. Influence of Prevailing Glucose Level	213
V. Combined Stimulation	214
1. Glucagon-Glucose Test	214
2. Glucagon-Meal Test	214
C. Comparison with Other Stimuli	214
I. Oral Glucose Tolerance Test	214
II. Intravenous Glucose Tolerance Test	215
III. Meal	215
IV. Other Tests	216
D. Clinical Applications	216
I. Insulin-Dependent Diabetes Mellitus	216
II. Non-Insulin-Dependent Diabetes Mellitus	217
III. Hypoglycemia	217
IV. Other Diseases	218
E. Conclusions	218
References	219

CHAPTER 14

Glucagon and the Control of Appetite

N. GEARY. With 2 Figures	223
A. Introduction	223
B. Prandial Glucagon Secretion	223
C. Glucagon Administration and Food Intake	225
I. Animal Studies	225
II. Human Studies	229
D. Glucagon Antagonism and Food Intake	229
E. Mechanism of Glucagon Satiety	231
I. Site of Action	231
II. Transduction	231
III. Hepatic Vagal Afferents	232
F. Clinical Aspects	233
I. Pathophysiology of Glucagon Satiety	233
II. Therapeutic Potential	233
G. Conclusions	234
References	234

CHAPTER 15

Glucagonoma and Its Management

A.J. SCHEEN and P.J. LEFÈBVRE	239
A. Introduction	239
B. Diagnosis and Localization of the Tumor	240
C. Management of the Glucagonoma Syndrome	242
I. Surgical Treatment	242
II. Vascular Occlusion	243
III. Radiation Therapy	243
IV. Chemotherapy	244
1. Streptozotocin	244
2. Dacarbazine	245
3. Others	246
V. Biological Therapy	246
VI. Antisecretory Peptide Therapy	247
VII. Symptomatic Treatment	248
D. Prognosis	248
E. Conclusions	249
References	250

CHAPTER 16

Structure and Function of the Glucagon-Like Peptide-1 Receptor

B. THORENS and C. WIDMANN. With 7 Figures	255
A. Introduction	255
B. GLP-1 Receptor	256
I. Structure	256
II. Tissue Distribution	258
III. Binding Characteristics	261
1. GLP-1 and Related Peptides	261
2. Exendins	261
IV. Coupling to Intracellular Second Messengers	262
V. Cross-talk Between the GLP-1 and Glucose-Signaling Pathways	264
VI. GLP-1 Versus GIP in the Stimulation of Insulin Secretion	266
VII. Regulation of Receptor Function	267
1. Regulated Expression	267
2. Desensitization	267
3. Internalization	267
VIII. GLP-1 in Non-Insulin-Dependent Diabetes	268
C. Conclusions	268
References	269

CHAPTER 17

Physiology and Pathophysiology of GLP-1

B. GÖKE, R. GÖKE, H.-C. FEHMANN, and H.-P. BODE

With 5 Figures	275
A. The Incretin Concept	275
B. Origin, Processing, Secretion and Fate of GLP-1	277
I. GLP-1 as Post-translational Product of Proglucagon Processing in Gut, Postsecretory Fate	277
II. Secretion of GLP-1	280
C. Tissue Distribution of GLP-1 Receptors and Biological Actions	282
I. General	282
II. Endocrine Pancreas	285
III. Lung	287
IV. Stomach	288
V. Brain	289
VI. Adipose Tissue	290
VII. Skeletal Muscle	291
VIII. Others	291
1. Exocrine Pancreas	291
2. Liver	291
D. Signal Transduction of the GLP-1 Receptor	291
I. cAMP Pathway	291
II. Calcium	293
E. Pathophysiological Relevance?	297
References	298

CHAPTER 18

Potential of GLP-1 in Diabetes Management

J.J. HOLST, M.A. NAUCK, C.F. DEACON, and C. ØRSKOV

With 2 Figures	311
A. Introduction	311
B. Actions of GLP-1 on Blood Glucose in Humans	314
C. Gastrointestinal Effects of GLP-1 in Humans	315
D. GLP-1 and Diabetes	316
I. Secretion	316
II. Receptors	316
III. Effects	317
E. GLP-1 Metabolism in Normal and Diabetic Subjects	320
F. Conclusion and Outlook	321
References	322

CHAPTER 19

Oxyntomodulin and Its Related Peptides

D. BATAILLE. With 5 Figures	327
A. Introduction	327
B. Biological Characteristics of Oxyntomodulin	327
I. Receptors	327
II. Acid Secretion	329
III. Biologically Active Moiety of Oxyntomodulin	330
IV. In Vivo Mode of Action: Interactions with Other Peptides	331
V. In Vitro Mode of Action	332
VI. Pharmacology: Search for a "Minimal Oxyntomodulin"	332
VII. Human Physiology and Pathophysiology: Oxyntomodulin-Like Immunoreactivity	333
VIII. Recent Developments	335
C. Conclusions	336
References	337
 Subject Index	 341